Sex, Vaccines, and Drug Prescriptions

Editor’s Note: This post by Ejura Salihu is the third in our Pharmaceutical Inequalities series. Ejura’s experience of a disrupted menstrual cycle post-COVID19 vaccination prompted her to write a much-needed commentary on why medical trials repeatedly overlook women’s needs and health. The Pharmaceutical Inequalities series is funded by the Holtz Center and the Evjue Foundation.

Read more

Disparities & Inequalities in Ending the HIV Epidemic: Pre-exposure Prophylaxis (PrEP)

Editor’s Note: This post by Maeleigh Tidd is the second in our Pharmaceutical Inequalities series. She explores the recent Ending the HIV Epidemic Initiative in the US, with a particular focus on prevention strategies, specifically PrEP, that are being implemented to assist in ending the epidemic. The Pharmaceutical Inequalities series is funded by the Holtz Center and the Evjue Foundation.

Read more

Psychedelics in the treatment of substance use disorders: the case of ibogaine for the treatment of opioid dependence.

Editor’s Note: This post by Anny Ortiz is the first in our Pharmaceutical Inequalities series. She explores the existing research landscape of psychedelics and then draws upon her own lived experience of working in a treatment center that offered ibogaine-assisted detoxification to discuss the affordances and unanswered questions of using psychedelics in treatment. The Pharmaceutical Inequalities series is funded by the Holtz Center and the Evjue Foundation.

Read more